臨床級低GI食品：無痛逆轉糖尿病前期

Clinical-Grade Low GI: Painlessly Reversing Pre-Diabetes

● 趨勢高度對齊：精準對接 2026 年最新美國飲食指南及全球公共營養政策趨勢。● 兆元市場切入：鎖定全球規模約 3.5兆台幣的麵條與特定休閒食品品項市場，填補代謝健康在主食與零食領域的巨大缺口。● 國際臨床驗證：專為穩定血糖與代謝健康研發，具備嚴謹科學實證的血糖友善食品。● 跨界營養創新： 以科學技術打破隔閡，完美連結「美味享受」與「血糖控制」；致力於在逾千億美元的澱粉紅海中，開創一片「臨床級低 GI」的藍海市場。● 垂直整合與技術護城河： 透過自建 FSSC 22000 認證工廠，全面垂直整合製造核心；藉由技術領先與規模化生產，建立長期的產業競爭優勢。

● Strategic Alignment: Synchronized with 2026 the latest U.S. Dietary Guidelines and emerging global nutritional policies.● Market Opportunity: Targeting the global noodle and snack sectors—a combined market exceeding $114B USD—addressing the critical unmet demand in metabolic health.● Clinically Validated: Scientifically formulated, low-GI foods designed to stabilize blood glucose and optimize metabolic health.● Innovation-Driven: Bridging the gap between sensory indulgence and glucose control; creating a "Clinical-Grade Low GI" blue ocean within the massive $114B global starch market.● Vertical Integration & Strategic Moat: Establishing our own FSSC 22000 certified facility for total manufacturing control; leveraging technological leadership and scalable production to build a long-term competitive moat.